Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | UBE2N | P61088 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29640209 | 0.95 | RXFP1 (0.56) | RXFP1MAOAMAOBPOLBSIGMAR1 | |
| SCHEMBL29712074 | 0.92 | RXFP1 (0.53) | RXFP1MAOAMAOBPOLBSIGMAR1 | |
| SCHEMBL28741971 | 0.91 | SIGMAR1 (0.53) | SIGMAR1SMN1; SMN2DPP4 | |
| SCHEMBL29640490 | 0.88 | RXFP1 (0.56) | RXFP1POLBSIGMAR1KMT2A | |
| SCHEMBL29640473 | 0.88 | RXFP1 (0.53) | RXFP1POLBSIGMAR1KMT2A | |
| SCHEMBL29640470 | 0.88 | RXFP1 (0.53) | RXFP1MAOAMAOBPOLBSIGMAR1 | |
| SCHEMBL29640457 | 0.87 | RXFP1 (0.56) | RXFP1MAOAMAOBPOLBSIGMAR1 | |
| SCHEMBL29640165 | 0.86 | POLB (0.57) | MAOAMAOBPOLBSIGMAR1MEN1 | |
| SCHEMBL28741977 | 0.86 | DPP4 (0.49) | RXFP1DPP4HSD17B10 | |
| SCHEMBL30104693 | 0.85 | RXFP1 (0.55) | RXFP1MAOAMAOBSIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | INSERM - INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (FR) | 2022-12-08 | — | — | US | disclosed |
| EP-4010341-A1 | TRKB POSITIVE ALLOSTERIC MODULATORS | Université de Strasbourg (FR) | 2022-06-15 | — | — | EP | disclosed |
| CN-114450006-A | TrkB positive allosteric modulators | 斯特拉斯堡大学 | 2022-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389019-A1 | TrkB POSITIVE ALLOSTERIC MODULATORS | HTT, NTRK2, BDNF | RXFP1 1822/4885MAOA 829/4885MAOB 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.